Perentesis Lab

Anderson, CP; Matthay, KK; Perentesis, JP; Neglia, JP; Bailey, HH; Villablanca, JG; Groshen, S; Hasenauer, B; Maris, JM; Seeger, RC; et al. Pilot study of intravenous melphalan combined with continuous infusion L-S,R-buthionine sulfoximine for children with recurrent neuroblastoma. Pediatric Blood and Cancer. 2015; 62:1739-1746.

Breese, EH; Krupski, C; Nelson, AS; Perentesis, JP; Phillips, CL. Use of CD19-directed CAR T-Cell Therapy in an Infant With Refractory Acute Lymphoblastic Leukemia. Journal of Pediatric Hematology/Oncology. 2021; 43:152-154.

Wunderlich, M; Manning, N; Sexton, C; O’Brien, E; Byerly, L; Stillwell, C; Perentesis, JP; Mulloy, JC; Mizukawa, B. PD-1 Inhibition Enhances Blinatumomab Response in a UCB/PDX Model of Relapsed Pediatric B-Cell Acute Lymphoblastic Leukemia. Frontiers in Oncology. 2021; 11.

Cunningham, S; McCauley, S; Vairamani, K; Speth, J; Girdhani, S; Abel, E; Sharma, RA; Perentesis, JP; Wells, SI; Mascia, A; et al. FLASH Proton Pencil Beam Scanning Irradiation Minimizes Radiation-Induced Leg Contracture and Skin Toxicity in Mice. Cancers. 2021; 13.

Sertorio, M; Nowrouzi, A; Akbarpour, M; Chetal, K; Salomonis, N; Brons, S; Mascia, A; Ionascu, D; McCauley, S; Kupneski, T; et al. Differential transcriptome response to proton versus X-ray radiation reveals novel candidate targets for combinatorial PT therapy in lymphoma. Radiotherapy and Oncology. 2021; 155:293-303.

Wright, KD; Yao, X; London, WB; Kao, PC; Gore, L; Hunger, S; Geyer, R; Cohen, KJ; Allen, JC; Katzenstein, HM; et al. A POETIC Phase II study of continuous oral everolimus in recurrent, radiographically progressive pediatric low-grade glioma. Pediatric Blood and Cancer. 2021; 68.

Williams, MT; Sugimoto, C; Regan, SL; Pitzer, EM; Fritz, AL; Mascia, AE; Sertorio, M; Vatner, RE; Perentesis, JP; Vorhees, CV. Whole brain proton irradiation in adult Sprague Dawley rats produces dose dependent and non-dependent cognitive, behavioral, and dopaminergic effects. Scientific Reports. 2020; 10.

Ullrich, NJ; Prabhu, SP; Reddy, AT; Fisher, MJ; Packer, R; Goldman, S; Robison, NJ; Gutmann, DH; Viskochil, DH; Allen, JC; et al. A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study. Neuro-Oncology. 2020; 22:1527-1535.

Jones, LM; O'Brien, MM; Breese, EH; Absalon, M; Burns, KC; Grimley, M; Mizukawa, B; Lee, LH; Perentesis, JP; Phillips, CL. Methylation profiling of hypomethylating agent response and treatment failure in pediatric and young adult MDS/AML. Journal of Clinical Oncology. 2020; 38:e22502-e22502.

Jones, LM; Melgar, K; Bolanos, L; Hueneman, K; Walker, MM; Jiang, J; Wilson, KM; Zhang, X; Shen, J; Jiang, F; et al. Targeting AML-associated FLT3 mutations with a type I kinase inhibitor. Journal of Clinical Investigation. 2020; 130:2017-2023.

Lawell, MP; Indelicato, DJ; Paulino, AC; Hartsell, W; Laack, NN; Ermoian, RP; Perentesis, JP; Vatner, R; Perkins, S; Mangona, VS; et al. An open invitation to join the Pediatric Proton/Photon Consortium Registry to standardize data collection in pediatric radiation oncology. British Journal of Radiology. 2020; 93.

Wunderlich, M; Manning, N; Sexton, C; Sabulski, A; Byerly, L; O'Brien, E; Perentesis, JP; Mizukawa, B; Mulloy, JC. Improved chemotherapy modeling with RAG-based immune deficient mice. PLoS ONE. 2019; 14.

Wunderlich, M; Chen, J; O'Brien, E; Manning, N; Sexton, C; Byerly, L; Perentesis, JP; Mizukawa, B; Mulloy, JC. Global Gene Expression and Mutation Signatures Are Preserved in PDX Models of Pediatric AML and Aid Discovery of Targeted Therapy for Cases with CBFA2T3/GLIS2 Rearrangement. Blood. 2019; 134:3766-3766.

Melgar, KM; Jones, LM; Walker, M; Bolanos, LC; Hueneman, K; Wunderlich, M; Jiang, J; Wilson, K; Zhang, X; Sutter, P; et al. Overcoming Adaptive Therapy Resistance in AML By Targeting Immune Response Pathways. Blood. 2019; 134:3934-3934.

O'Brien, E; VanCauwenbergh, B; Alexander, J; Basu, M; Wunderlich, M; Sarangdhar, M; Mizukawa, B; Perentesis, JP. Modeling Effective AML Therapies - Comparative Anti-Leukemic Synergy of BCL2 and MCL1 Inhibition Combined and with Chemotherapy. Blood. 2019; 134:3370-3370.

Melgar, K; Walker, MM; Jones, LM; Bolanos, LC; Hueneman, K; Wunderlich, M; Jiang, J; Wilson, KM; Zhang, X; Sutter, P; et al. Overcoming adaptive therapy resistance in AML by targeting immune response pathways. Science Translational Medicine. 2019; 11.

Widemann, BC; Lu, Y; Reinke, D; Okuno, SH; Meyer, CF; Cote, GM; Chugh, R; Milhem, MM; Hirbe, AC; Kim, A; et al. Targeting Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) in a Phase II Study of Everolimus in Combination with Bevacizumab (SARC016). Sarcoma. 2019; 2019.

Sertorio, M; Perentesis, JP; Vatner, RE; Mascia, AE; Zheng, Y; Wells, SI. Cancer Cell Metabolism: Implications for X-ray and Particle Radiation Therapy. International journal of particle therapy. 2019; 5:40-48.

Meyer, SE; Muench, DE; Rogers, AM; Newkold, TJ; Orr, E; O'Brien, E; Perentesis, JP; Doench, JG; Lal, A; Morris, PJ; et al. miR-196b target screen reveals mechanisms maintaining leukemia stemness with therapeutic potential. Journal of Experimental Medicine. 2018; 215:2115-2136.

Zhang, C; D'Alessandro, A; Wellendorf, AM; Mohmoud, F; Serrano-Lopez, J; Perentesis, JP; Komurov, K; Alexe, G; Stegmaier, K; Whitsett, JA; et al. KLF5 controls glutathione metabolism to suppress p190-BCR-ABL+ B-cell lymphoblastic leukemia. Oncotarget. 2018; 9:29665-29679.

Weber, DC; Habrand, JL; Hoppe, BS; Kayser, CH; Laack, NN; Langendijk, JA; MacDonald, SM; McGovern, SL; Pater, L; Perentesis, JP; et al. Proton therapy for pediatric malignancies: Fact, figures and costs. A joint consensus statement from the pediatric subcommittee of PTCOG, PROS and EPTN. Radiotherapy and Oncology. 2018; 128:44-55.

Hess, CB; Indelicato, DJ; Paulino, AC; Hartsell, WF; Hill-Kayser, CE; Perkins, SM; Mahajan, A; Laack, NN; Ermoian, RP; Chang, AL; et al. An Update From the Pediatric Proton Consortium Registry. Frontiers in Oncology. 2018; 8.

Dixon, SB; Lane, A; O'Brien, MM; Burns, KC; Mangino, JL; Breese, EH; Absalon, MJ; Perentesis, JP; Phillips, CL. Viral surveillance using PCR during treatment of AML and ALL. Pediatric Blood and Cancer. 2018; 65.

Geller, JI; Perentesis, JP; Liu, X; Minard, CG; Kudgus, RA; Reid, JM; Fox, E; Blaney, SM; Weigel, BJ. A phase 1 study of the c-Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111). Pediatric Blood and Cancer. 2017; 64.

Lobeck, I; Rymeski, B; Burns, K; Nagarajan, R; Correll, J; Kent, D; Dasgupta, R. Long-term morbidity after staging laparotomy for Hodgkin lymphoma. Journal of Pediatric Surgery. 2017; 52:1430-1432.

Mizuno, T; Fukuda, T; Christians, U; Perentesis, JP; Fouladi, M; Vinks, AA. Population pharmacokinetics of temsirolimus and sirolimus in children with recurrent solid tumours: a report from the Children's Oncology Group. British Journal of Clinical Pharmacology. 2017; 83:1097-1107.

Weiss, BD; Scott, M; Demmel, K; Kotagal, UR; Perentesis, JP; Walsh, KE. (2017) Significant and Sustained Reduction in Chemotherapy Errors Through Improvement Science. 13:e329-e336.

Hickey, V; Best, D; Osterkamp, E; Beckett, A; Flesch, L; Demmel, KM; Myers, W; Davies, SM; Perentesis, J; Dandoy, CE. 521 Quality Improvement Initiative to Improve Adherence to Activities of Daily Living (ADL) in Pediatric Bone Marrow Transplant (BMT) Patients. Biology of Blood and Marrow Transplantation. 2017; 23.